Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Genmab A/S (GMAB)

44.4   0.28 (0.63%) 01-17 17:26
Open: 43.32 Pre. Close: 44.12
High: 44.83 Low: 43.11
Volume: 1,276,043 Market Cap: 28,767M
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 44.884 - 45.056 45.056 - 45.229
Low: 42.662 - 42.866 42.866 - 43.071
Close: 44.066 - 44.383 44.383 - 44.701

Technical analysis

as of: 2021-01-15 4:41:04 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 52.36     One year: 61.16
Support: Support1: 40.78    Support2: 38.27
Resistance: Resistance1: 44.83    Resistance2: 52.36
Pivot: 41.29
Moving Average: MA(5): 42.89     MA(20): 40.95
MA(100): 37.67     MA(250): 31.74
MACD: MACD(12,26): 1.28     Signal(9):
Stochastic oscillator: %K(14,3): 97.38     %D(3): 89.38
RSI: RSI(14): 71.19
52-week: High: 44.83  Low: 16.24  Change(%): 96.6
Average Vol(K): 3-Month: 47672  10-Days: 56317

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
GMAB has closed above the upper band by 0.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 42.7% wider than normal. The large width of the bands suggest high volatility as compared to GMAB's normal range. The bands have been in this wide range for 0 bars. This is a sign that the current trend might continue.

Headline News

Fri, 15 Jan 2021
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis - GlobeNewswire

Fri, 15 Jan 2021
First Week of March 19th Options Trading For Genmab (GMAB) - Nasdaq

Wed, 13 Jan 2021
Genmab A/S (GMAB) Achieves $40 Million Milestone in Collaboration with AbbVie -

Wed, 06 Jan 2021
Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo Finance

Tue, 05 Jan 2021
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer | Antibodies | News Channels -

Tue, 05 Jan 2021
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug - Yahoo Finance

Financial Analysis

Growth n/a
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability n/a
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency n/a
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Neutral Discounted cash flow: Neutral
Return on Assets: Neutral Price to Earnings: Neutral
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 655
Shares Float (M) 646
% Held by Insiders
% Held by Institutions 6.32
Shares Short (K) 595
Shares Short P. Month (K) 775

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin 51.22
Operating Margin
Return on Assets (ttm) 27.3
Return on Equity (ttm) 36.5
Qtrly Rev. Growth 65.8
Gross Profit (p.s.) 8.193
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth -1.30
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio 2.48
Price to Book value
Price to Sales
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.